The Oslo University Hospital, has been included as a site in the ongoing ONCOS-102 trial in anti-PD1 refractory, advanced melanoma.

Recently, Targovax reported encouraging results from Part 1 of the phase I trial in anti-PD1 refractory melanoma combining ONCOS-102 with the checkpoint inhibitor Keytruda, showing 33% ORR and robust immune activation. The trial has been running at three well reputed hospitals on the US East Coast.

Part 2 of the trial is currently enrolling patients, where an extended ONCOS-102 dosing regimen is being assessed. Targovax has now received all the necessary approvals and documentation required to open Oslo University Hospital, in Part 2 of the trial.

“As a Norwegian company, we are happy to open Oslo as a site for our ONCOS-102 melanoma trial. The trial has shown promising early data, and we are very pleased to be able to offer trial participation and this treatment option to Norwegian melanoma patients. We believe Oslo University Hospital will be a great addition to the trial consortium and facilitate faster recruitment in Part 2 of the trial,” says Magnus Jäderberg, CMO of Targovax.